Drug Trial Radar · NCT07221149
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
690
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Nov 8, 2030
Study completion Sep 11, 2032
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Oct 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Interventions
PumitamigDrug
Specified dose on specified days
FolfoxDrug
Specified dose on specified days
CapoxDrug
Specified dose on specified days
NivolumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentTime frame: Up to 2 years after the last participant is randomized
- Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)Time frame: Up to approximately 33 months
- Overall survival (OS)Time frame: Up to approximately 47 months
Locations
161 sites in 20 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California · Recruiting
Local Institution - 0428
San Francisco, California · Not yet recruiting
Florida Cancer Specialists - South
Fort Myers, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Florida Cancer Specialists - North
St. Petersburg, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Local Institution - 0379
Chicago, Illinois · Not yet recruiting
Local Institution - 0268
Iowa City, Iowa · Not yet recruiting
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota · Recruiting
Missouri Cancer Associates
Columbia, Missouri · Recruiting
University Of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Local Institution - 0274
Rochester, New York · Not yet recruiting
University of North Carolina Medical Center
Chapel Hill, North Carolina · Recruiting
Local Institution - 0443
Cleveland, Ohio · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oncology Associates Of Oregon, Pc
Eugene, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
Texas Oncology - Amarillo Cancer Center
Amarillo, Texas · Recruiting
Texas Oncology-Austin Central
Austin, Texas · Recruiting
Texas Oncology
Beaumont, Texas · Recruiting
Texas Oncology - Northeast Texas
Denison, Texas · Recruiting
Texas Oncology - DFW
Grapevine, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Oncology - San Antonio
San Antonio, Texas · Recruiting
Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem
Salem, Virginia · Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin · Recruiting
Local Institution - 0300
· Not yet recruiting
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
Buenos Aires, Argentina · Recruiting
Centro Médico Fleischer
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
ABB, Buenos Aires F.D., Argentina · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.